Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Canakinumab vs placebo Time between attacks · people with colchicine‐resistant familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | NR | No studies |
Canakinumab vs placebo Prevention of AA amyloidosis · people with colchicine‐resistant familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | NR | No studies |
Colchicine single dose vs divided dose Number of participants experiencing an attack · children with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | NR | No studies |
Colchicine single dose vs divided dose Time between attacks · children with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | NR | No studies |
Colchicine single dose vs divided dose Prevention of AA amyloidosis · children with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | NR | No studies |
Colchicine (oral) vs placebo Prevention of AA amyloidosis · people with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | NR | No studies |
Colchicine (oral) vs placebo Acute‐phase response · people with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | NR | No studies |
Topical clonidine (TC) vs active comparator Much or very much improved on PGIC during longest · adults with painful diabetic neuropathy Topical clonidine for neuropathic pain in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Topical clonidine (TC) vs active comparator Very much improved on PGIC during longest · adults with painful diabetic neuropathy Topical clonidine for neuropathic pain in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Topical clonidine (TC) vs active comparator Withdrawals due to adverse events during longest · adults with painful diabetic neuropathy Topical clonidine for neuropathic pain in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Topical clonidine (TC) vs active comparator Participants experiencing at least 1adverse event during longest · adults with painful diabetic neuropathy Topical clonidine for neuropathic pain in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Topical clonidine (TC) vs active comparator Withdrawal due to lack of efficacy (12 weeks) · adults with painful diabetic neuropathy Topical clonidine for neuropathic pain in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Topical clonidine (TC) vs active comparator Participant‐reported pain relief of 30% or greater during longest · adults with painful diabetic neuropathy Topical clonidine for neuropathic pain in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Remifentanil vs diazepam Perinatal mortality · health problem or population Perioperative pharmacological interventions for fetal immobilisation during fetal surgery and invasive… (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Remifentanil vs diazepam Time taken to perform procedure · health problem or population Perioperative pharmacological interventions for fetal immobilisation during fetal surgery and invasive… (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: unconditional cash transfers vs conditional cash transfers: primary outcomes Is moderately stunted · children (0 to 17 years) and adults (≥ 18 years) or households Unconditional cash transfers for reducing poverty and vulnerabilities: effect on use of health services and… (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: unconditional cash transfers vs conditional cash transfers: primary outcomes Has died · children (0 to 17 years) and adults (≥ 18 years) or households Unconditional cash transfers for reducing poverty and vulnerabilities: effect on use of health services and… (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: unconditional cash transfers vs conditional cash transfers: primary outcomes Has been food secure · children (0 to 17 years) and adults (≥ 18 years) or households Unconditional cash transfers for reducing poverty and vulnerabilities: effect on use of health services and… (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: unconditional cash transfers vs conditional cash transfers: primary outcomes Level of depression · children (0 to 17 years) and adults (≥ 18 years) or households Unconditional cash transfers for reducing poverty and vulnerabilities: effect on use of health services and… (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: unconditional cash transfer vs no unconditional cash transfer: primary outcomes Has died · children (0 to 17 years) and adults (≥ 18 years) or households Unconditional cash transfers for reducing poverty and vulnerabilities: effect on use of health services and… (2022) · Cochrane | no estimate extracted | NR | No studies |
Corticosteroids vs no corticosteroid use Longer term (> 1 year after disease onset) coronary morbidity (non‐aneurysmal) · children diagnosed with Kawasaki disease Corticosteroids for the treatment of Kawasaki disease in children (2022) · Cochrane | no estimate extracted | NR | No studies |
Binocular iPad treatment vs occlusion therapy Change in distance BCVA in the amblyopic eye 12 months after cessation of treatment · 5‐ to 8‐year‐old children with amblyopia Binocular versus standard occlusion or blurring treatment for unilateral amblyopia in children aged three to… (2022) · Cochrane | no estimate extracted | NR | No studies |
Binocular iPad treatment vs occlusion therapy Change in the interocular difference in contrast sensitivity Any validated test, from baseline to 16 (± 2) weeks · 5‐ to 8‐year‐old children with amblyopia Binocular versus standard occlusion or blurring treatment for unilateral amblyopia in children aged three to… (2022) · Cochrane | no estimate extracted | NR | No studies |
Binocular iPad treatment vs occlusion therapy Measurable change in stereopsis after 8 (± 2) weeks and 16 (± 2) weeks of intervention 'Real change' in stereopsis is defined as a change in stereoacuity of two or more octaves. · 5‐ to 8‐year‐old children with amblyopia Binocular versus standard occlusion or blurring treatment for unilateral amblyopia in children aged three to… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Comparison (reference treatment) · adults and children with focal seizures Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Comparison (reference treatment) · adults and children with focal seizures Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Comparison (reference treatment) · adults and children with generalised seizures* Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Live birth or ongoing pregnancy: early (EFP) vs late (LFP) follicular phase · infertile women or couples attempting to conceive through sexual intercourse or intrauterine insemination (IUI) Endometrial injury for pregnancy following sexual intercourse or intrauterine insemination (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Live birth or ongoing pregnancy: prior cycle vs IUI cycle · infertile women or couples attempting to conceive through sexual intercourse or intrauterine insemination (IUI) Endometrial injury for pregnancy following sexual intercourse or intrauterine insemination (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Pain during the procedure · infertile women or couples attempting to conceive through sexual intercourse or intrauterine insemination (IUI) Endometrial injury for pregnancy following sexual intercourse or intrauterine insemination (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings for cholinesterase inhibitors vs placebo Economic outcomes · People with Parkinson's disease Interventions for preventing falls in Parkinson's disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings for education vs control Rate of falls (falls per person‐year) · People with Parkinson's disease Interventions for preventing falls in Parkinson's disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings for education vs control Number of people sustaining one or more fall‐related fractures · People with Parkinson's disease Interventions for preventing falls in Parkinson's disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings for education vs control Quality of life · People with Parkinson's disease Interventions for preventing falls in Parkinson's disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings for education vs control Adverse events · People with Parkinson's disease Interventions for preventing falls in Parkinson's disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings for education vs control Economic outcomes · People with Parkinson's disease Interventions for preventing falls in Parkinson's disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR All‐cause mortality · children and adolescents with obesity Surgery for the treatment of obesity in children and adolescents (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Socioeconomic effects · children and adolescents with obesity Surgery for the treatment of obesity in children and adolescents (2022) · Cochrane | no estimate extracted | NR | No studies |
Autologous myeloablative selective HSCT vs cyclophosphamide Pulmonary arterial hypertension · people with systemic sclerosis Stem cell transplantation for systemic sclerosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Autologous non‐myeloablative non‐selective HSCT vs cyclophosphamide Event‐free survival · people with systemic sclerosis Stem cell transplantation for systemic sclerosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Autologous non‐myeloablative non‐selective HSCT vs cyclophosphamide Functional ability – HAQ‐DI Scale 0–3 with 0 representing no/mild impairment and 3 representing very severe impairment. The study incorporated a ≥ 0.4 threshold · people with systemic sclerosis Stem cell transplantation for systemic sclerosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Autologous non‐myeloablative non‐selective HSCT vs cyclophosphamide Pulmonary arterial hypertension · people with systemic sclerosis Stem cell transplantation for systemic sclerosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Autologous non‐myeloablative selective HSCT vs cyclophosphamide Pulmonary arterial hypertension · people with systemic sclerosis Stem cell transplantation for systemic sclerosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Adjunctive therapies in addition to land‐based exercise therapy vs land‐based exercise therapy Withdrawals due to adverse events · osteoarthritis of the hip or knee Adjunctive therapies in addition to land‐based exercise therapy for osteoarthritis of the hip or knee (2022) · Cochrane | no estimate extracted | NR | No studies |
Active rPMS only vs sham rPMS Activities of daily living (ADLs) · people with stroke Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Active rPMS only vs no intervention Lower limb function · people with stroke Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Active rPMS only vs no intervention Spasticity (elbow) · people with stroke Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Active rPMS only vs no intervention Spasticity (wrist) · people with stroke Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Active rPMS only vs no intervention Muscle strength · people with stroke Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Active rPMS only vs no intervention Death · people with stroke Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |